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Abstract 
Background: Over the last twenty years, the efforts of the scientific community devoted to the 
comprehension and treatment of ovarian cancer have remained poorly remunerative, with the 
case-fatality ratio of this disease remaining disappointedly high. Limited knowledge of the basic principles 
regulating ovarian carcinogenesis and factors impacting the course of disease may significantly impair 
our ability to intervene in early stages and lessen our expectations in terms of treatment outcomes. In 
the present study, we sought to assess whether metabolic factors and anthropometric indicators, i.e., 
pre-treatment fasting glucose and body mass index, are associated with renown cancer related prog-
nostic factors such as tumour stage and grade at diagnosis.  
Materials and Methods: Study participants were 147 women diagnosed with epithelial ovarian 
cancer and treated with platinum based regimens and/or surgery at the Regina Elena National Cancer 
Institute of Rome, Italy. Glucose levels were assessed at the institutional laboratories on venous blood 
collected in overnight fasting conditions and prior to any therapeutic procedure. Stage was coded 
according to the FIGO staging system based on the results of the diagnostic workup, while tumour 
grade was locally assessed by an expert pathologist. Participants' characteristics were descriptively 
analyzed for the overall study population and in a subgroup of 70 patients for whom data on body mass 
index (BMI) were available. FIGO stage and grade were compared by categories of pre-treatment fasting 
glucose defined upon the median value, i.e., 89 mg/dl. The association of interest was tested in re-
gression models including BMI. 
Results: For the overall study population, patients in the lowest category of fasting glucose were sig-
nificantly more likely to exhibit a FIGO stage III-IV at diagnosis compared with their counterpart in the 
highest glucose category (81.3 vs 66.7%, p: 0.021). Subgroup analysis in 70 patients with BMI data 
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confirmed this association (81.5 vs 55.8, p: 0.049), which remained significant when tested in regression 
models including BMI (OR: 0.28 95% CI 0.086-0.89, p: 0.031). No relevant evidence emerged when 
testing the association between fasting glucose and tumour grade. 
Conclusions: In patients diagnosed with epithelial ovarian cancer, pre-treatment glucose levels appear 
to be inversely associated with FIGO stage. Further studies are warranted to eventually confirm and 
correctly interpret the implications of this novel finding. 
Key words: epithelial ovarian cancer, fasting glucose, body mass index, FIGO stage, tumour grade 
Background 
Despite intensive efforts from the scientific 
community, statistics for ovarian cancer have re-
mained fairly stable in European countries over the 
past two decades, with the contribution paid to this 
disease in terms of specific mortality being still unac-
ceptably high. Major difficulties in diagnosis and 
therapeutic management might at least partly arise 
from limited knowledge of the basic principles regu-
lating ovarian carcinogenesis and factors impacting 
the course of disease. When translated to the clinical 
setting, such limitations may significantly impair our 
ability to intervene in early disease stages and lessen 
our expectations in terms of treatment outcomes [1]. 
The role played by metabolic determinants and 
anthropometric factors in epithelial ovarian cancer 
(EOC) represents an increasingly attractive area of 
investigation. Body mass index (BMI) is by far the 
most commonly assessed anthropometric indicator in 
association with estimates of ovarian cancer risk 
and/or mortality. Epidemiologic evidence from large 
prospective cohort studies generally [2-3], although 
not exclusively [4], supports the role of BMI as a rel-
evant risk factor for EOC. When considered in light of 
cancer histology and grade, BMI has been positively 
associated with increased risk in the less common 
subtypes, i.e., borderline serous, invasive endometri-
oid and invasive mucinous epithelial ovarian cancers, 
while no association has emerged with high grade 
serous invasive cancer [5]. Notwithstanding the well 
established link between BMI and glucose levels, 
there is limited evidence concerning the simultaneous 
consideration of anthropometric indicators and bi-
omarkers of systemic energetic metabolism in studies 
aimed at risk assessment for EOC. To our knowledge, 
the only available data are from a large cohort in-
cluding 287,320 women. The authors found no evi-
dence in support of the overall association between 
risk of developing EOC and metabolic syndrome de-
fined based on the standardized sum of pre-set scores 
for BMI, blood pressure, glucose, cholesterol and tri-
glycerides. Conversely, women with metabolic syn-
drome showed a higher risk of death by the disease if 
younger than 50 years, while increasing levels of BMI 
conferred increased risk of death by ovarian cancer in 
women aged 50 years and older. No evidence 
emerged concerning the association between fasting 
glucose and ovarian cancer risk [6].  
Growing data from the preclinical setting pro-
vide a plausible rationale on how metabolic and an-
thropometric determinants may be placed within 
pathways mechanistically involved in EOC develop-
ment and progression. An emerging view of carcino-
genesis relies on the importance of tumour environ-
ment in cancer development. Deregulation in glucose 
metabolism may have significant effects on the onset 
and evolution of EOC. The underlying mechanisms 
have been widely explored at the cellular level, 
whereas there is still paucity of data from in vivo ex-
periments and from the clinical setting. Indirect evi-
dence on glucose metabolism and EOC also stems 
from the inveterate use of a number of antihypergly-
cemic agents currently available for blood glucose 
control in patients with metabolic disturbances. Due 
to their ability to impair glucose availability to the 
tumour, antihyperglycemic drugs such as metformin 
have been increasingly explored for their potentials as 
anticancer agents. These drugs have also been shown 
to have direct effects on metabolic and signaling 
pathways not necessarily mediated by their action on 
glucose levels and availability. Evidence from clinical 
studies is particularly suggestive in diabetic women 
with ovarian cancer. In these patients, the use of 
metformin is associated with a reduced risk of cancer 
and improved survival [7-11].  
On this basis, we sought to explore the associa-
tion between pre-treatment fasting glucose, consid-
ered as a proxy for systemic energy metabolism, and 
widely recognized prognostic factors such as FIGO 
stage and grade at diagnosis in a historic cohort of 
patients with EOC for whom data were available for 
the variables of interest. The impact of anthropometric 
determinants on the association under evaluation was 
also assessed in a subgroup of patients for whom BMI 
data had been collected at baseline. 
Methods 
The present analysis includes data on 147 pa-
tients with clinically annotated EOC diagnosed 
and/or treated at the Regina Elena National Cancer 
Institute of Rome (Central Italy) between May 2005 
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and September 2013. To the purpose of the present 
study, a trained research assistant retrieved medical 
records on patient-and cancer-related features. Data 
on fasting glucose were considered suitable for our 
analysis if all the following conditions were satisfied: 
1. Glucose levels had been assessed at baseline, that is, 
prior to any therapeutic procedures; 2. Blood drawing 
had occurred in overnight fasting conditions and in 
the time window between 7.00 and 10.00 AM; 3. The 
assessment had been performed at the institutional 
laboratories where glucose levels had been assessed 
by hexokinase reagent using a Cobas analyzer and a 
(Roche Diagnostics). Abnormalities in glucose me-
tabolisms were identified based on the reported use of 
antidiabetic medications and/or fasting plasma glu-
cose levels greater than 126 mg/dl [12]. Cancer stage 
was codified according to the FIGO staging system for 
ovarian cancer based on the results of the diagnostic 
workup, while tumour histology and grade were lo-
cally assessed by an expert pathologist. Data on de-
mographics were obtained through cross linking to 
the institutional platform for administrative records, 
i.e., hospital discharge records. When available, BMI 
data were integrally extracted from the clinical rec-
ords or computed as weight in kilograms divided by 
the square of height in meters.  
Statistical analysis  
Distributions were examined and descriptive 
statistics computed for all the variables of interest. 
The characteristics of the study participants were re-
ported for the entire historic cohort (N=147). Fasting 
glucose was addressed as a categorical variable whose 
modalities were defined upon the median value 
computed in the study population, i.e., 89 mg/dl. 
Means and standard deviations were used for con-
tinuous data while frequencies and percentage values 
for categorical data. Existing differences between 
mean values were evaluated using the T- Student or 
One Way Anova test according to the number (2 or 
more) of groups compared. We used the Pearson's 
Chi-squared test of independence or Fisher’s exact 
test (2-tailed) to assess the relationship between cate-
gorical variables. We tested several variables for as-
sociation with FIGO stage and tumour grade using 
univariate logistic regression analysis. Multivariate 
models were then built by including those factors 
testing significant at the univariate analysis and/or 
for which evidence of a putative role on the associa-
tion of interest was supported by the available litera-
ture (e.g. menopausal status, histology). Menopausal 
status was self reported. To the purposes of our anal-
ysis, the histologic subtype was addressed as a cate-
gorical variable including two modalities only, i.e., 
serous vs non-serous EOC. This was due to the par-
ticularly limited number of non-serous EOC which all 
converged into a unique category finally including 17 
cases. Given the prognostic role of diabetes mellitus in 
EOC, in a subsequent round of analyses, patients with 
abnormalities in glucose metabolism were identified 
and excluded [10, 12]. Data on BMI were exclusively 
available for 70 EOC patients. In this subset, we vali-
dated the results from the overall cohort according to 
same statistical and methodological approach. We 
considered p values less than 0.05 statistically signif-
icant. All statistical analyses were performed with the 
SPSS statistical software version 21 (SPSS inc., Chica-
go, IL). 
Results 
The descriptive characteristics of the overall co-
hort are reported in table 1. Means and standard de-
viations for age at diagnosis (years) and fasting glu-
cose (mg/dl) were 57.5 (±11.6) and 93.6 (±20.5), re-
spectively. As expected, the vast majority of our pa-
tients were diagnosed with a serous histological sub-
type and fell in the highest grade category. 
 
Table 1. Descriptive characteristics of the study participants 
(N:147). 
 mean±SD 
Age (years) 57.5±11.6 
1Fasting Glucose  93.6±20.5 
 N (%) 
Histologic Subtype   
Serous 130 (88.4) 
Poorly differentiated 4 (2.7) 
Endometriod 1 (0.7) 
Clear Cell 1 (0.7) 
Other 11 (7.5) 
2FIGO stage  
I 22 (15.0) 
II 16 (11.0) 
III-IV 109 (74.0) 
Tumour Grade  
I-II 42 (28.6) 
III 105 (71.4) 
1mg/dl: milligrams/deciliter; 2 FIGO: International Federation of Gynecology and 
Obstetrics 
 
 
In table 2, FIGO stage is reported by categories of 
pre-treatment fasting glucose defined upon the me-
dian value for this study population, i.e., 89.0 mg/dl. 
Women whose levels of glycemia were in the lowest 
category were significantly more likely to be affected 
by a stage III-IV tumour compared with their coun-
terpart in the highest glycemic category (81.3 vs 
66.7%, p=0.021). Conversely, tumour grade seemed 
not to be affected by baseline fasting glucose (p=0.876) 
(table 3). The association between fasting glucose and 
FIGO stage was confirmed in a subset of 70 patients 
for whom BMI data were available (81.5 vs 55.8%, 
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p=0.049, table 4) and remained significant when test-
ed in regression models including BMI (OR: 0.28 95% 
CI 0.086-0.89, p: 0.031). Univariate analysis showed 
confirmatory findings for the association of fasting 
glucose and FIGO stage (OR: 0.46, 95% CI: 0.21-0.98, 
p=0.045), while no significant evidence emerged con-
cerning a putative role of age at diagnosis, histological 
subtype and menopause (table 5). To assess whether 
the associations tested were at least partly driven by 
the presence of patients with abnormalities in glucose 
metabolism, the entire set of analysis was repeated 
following exclusion of ten patients from the original 
cohort. The results obtained did not differ from those 
previously observed at any extent (supplementary 
table 1). 
 
Table 2. Tumour FIGO stage by categories of fasting glucose 
(N:147). 
 2FIGO stage  
I II III - IV Chi2 
N=22 N=16 N=109 p-value 
n (%) n (%) n (%)  
1Fasting Glucose     
≤189 11 (14.7) 3 (4.0) 61 (81.3) 0.021 
>89 11 (15.3) 13 (18.1) 48 (66.7)  
1in mg/dl: milligrams/deciliter; 2International Federation of Gynecology and 
Obstetrics 
 
Table 3. Tumour grade by categories of fasting glucose (N=147). 
 2G  
G1 – G2 G3 Chi2 
N=42 N=105 p-value 
n (%) n (%)  
1Fasting Glucose    
≤189 21 (28.0) 54 (72.0) 0.876 
>89 21 (29.2) 51 (70.8)  
1mg/dl: milligrams/deciliter; 2 Grade 
 
Table 4. Tumour FIGO stage by categories of fasting glucose in 
epithelial ovarian cancer patients with available data on body mass 
index (N:70). 
 1FIGO  
I II III - IV Chi2 
N=13 N=11 N=46 p-value 
n (%) n (%) n (%)  
Glycaemia at the baseline     
≤189 4 (14.8) 1 (3.7) 22 (81.5) 0.049 
>89 9 (20.9) 10 (23.3) 24 (55.8)  
1International Federation of Gynecology and Obstetrics; 2mg/dl: milli-
grams/deciliter 
 
Discussion 
We sought to verify the association of proxies of 
systemic energy metabolism and renown dis-
ease-related prognostic factors in a historic cohort of 
147 women diagnosed with EOC at the Regina Elena 
National Cancer Institute between May 2005 and 
September 2013. The exposure of interest was 
pre-treatment fasting glucose, while tumour stage and 
grade were identified among the prognostic deter-
minants for which medical records were available. We 
found novel evidence of a significant inverse associa-
tion between fasting glycemia and FIGO stage at di-
agnosis in the overall study cohort. Results were con-
firmed in subgroup analysis including patients with 
anthropometric data and remained statistically sig-
nificant in multivariate models including BMI. Con-
versely, no evidence of an influence of glucose levels 
on tumour grade emerged either in the entire cohort 
or in subgroup analysis. No significant evidence was 
found in support of any associations between fasting 
glucose and age at diagnosis, histological subtype and 
menopause. Our results were not affected by the ex-
clusion of 10 patients identified on the basis of glucose 
dismetabolisms as defined by altered glucose levels 
and/or reported use of antidiabetic drugs.  
 
 
Table 5. Univariate analysis of factors associated with FIGO stage 
at diagnosis (N=147). 
  2OR 395%CI p-value 
1Fasting Glucose ≤89 1   
 >89 0.46 0.25-0.98 0.045 
Age at Diagnosis  0.98 0.95-1.01 0.281 
     
Histological Subtype Other 1   
 Serous 0.58 0.16-2.15 0.416 
     
Menopause Premenopausal 1   
 Postmenopausal 0.70 0.29-1.70 0.434 
1mg/dl: milligrams/deciliter; 2OR: Odds Ratios; 395% CI: 95% Confidence Interval 
 
 
Our first time finding of an inverse association 
between pre-treatment glucose levels and FIGO stage 
in EOC is of non univocal interpretation. In non dia-
betic patients with advanced stage tumours, glucose 
levels in the lower range may be a sign of systemic 
impairment with reflections on liver functions and 
altered gluconeogenesis. This is generally accompa-
nied by loss of weight, with a basically low BMI and 
scarce performance status. On this basis, in a set of 
adjunctive analyses, we verified whether FIGO stage 
was affected by BMI and performance status (PS) as 
evaluated based on the Eastern Cooperative Oncology 
Group (ECOG) scale. Data were available only for a 
subgroup of the original cohort (n=70). No evidence 
emerged concerning any association between ECOG 
performance status and stage at diagnosis. In more 
detail, as a result of the clinical evaluation performed 
at baseline, these patients had been all assigned to the 
first two categories of the ECOG scale (data available 
upon request). Similarly, our ad hoc analysis did not 
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support any association between BMI and FIGO stage 
(supplementary table 2). In addition, since our results 
were not affected by the exclusion of 10 women with 
glucose dismetabolism (supplementary table 1), we 
may exclude that our results were driven by the in-
appropriate glycemic control occurring in this subset 
of patients.  
As an alternative hypothesis, glucose levels in 
the lower range might represent indirect evidence of 
accelerated glucose transport and increase glucose 
uptake related to enhanced expression of the protein 
transporter protein 1 (GLUT1) in EOC with advanced 
FIGO stage at diagnosis. GLUT 1 is a hexose trans-
porter ascribed to the GLUT family, which includes 
fourteen facilitative transporters working along the 
glucose concentration gradient [13-14]. Among them, 
GLUT1 is the most widely expressed and is involved 
in maintaining basal glucose transport in several 
normal cell types and cancer cells [15-20]. The exist-
ence of a significant correlation between increased 
expression of GLUT1 in serous adenocarcinomas of 
the ovary and FIGO stage has been consistently 
shown in previous research. Cai and colleagues 
worked on two hundred formalin-fixed, paraf-
fin-embedded sections from 40 normal ovarian tis-
sues, 40 serous cystoadenomas, 40 borderline serous 
cystoadenomas and 80 serous cystoadenocarcinomas. 
In their study, results from immunostaining with 
rabbit anti-GLUT1 polyclonal antibody showed in-
creased expression of GLUT1 and p63, a homolog of 
p53, in cystoadenocarcinomas compared to benign 
serous and borderline cystoadenomas. In addition, 
overexpression of GLUT1 and p63 were associated 
with the FIGO stage and metastasis of the tumors [21]. 
Similar results were reported by Shao and colleagues 
[22]. Hitherto, no study has evaluated whether in high 
FIGO stage EOC the increased expression of GLUT1 
had any sort of resonance on the expression of this 
same receptor in other districts and/or at the systemic 
level. GLUT1 is physiologically over-expressed at the 
interface with cells or tissues with a glucose-driven 
metabolism, e.g. red blood cells membrane, perineum 
of the peripheral nerves. On a still highly speculative 
reasoning, we might hypothesize a sort of homeo-
static equilibrium and the occurrence of consensual 
changes in the expression of this receptor at a multi-
district level following metabolic adaption of the 
ovary to the enhanced energy necessities dictated by 
the carcinogenetic process.  
When moving to the opposite side of a normal 
glycemic interval, the evidence of glucose levels in the 
higher range of fasting glucose in patients diagnosed 
with low FIGO stage EOC might encourage investi-
gating the gynecological district for screening pur-
poses in non-diabetic, asymptomatic women. Under 
the putative umbrella of confirmatory results from 
further studies, this approach might further inform 
the allocation of these women to categories differing 
by risk of EOC development. Given its favorable 
cost-benefit balance, the evaluation of indicators of 
the systemic metabolic asset jointly with anthropo-
metric measurements might be proposed as an easy 
and efficacious integration to the most updated, 
though still not univocally clarified, orientations and 
guidelines for ovarian cancer screening [23-24].  
Our results are barely comparable to previous 
findings. To the best of our knowledge, no prior 
studies have addressed the association between fast-
ing glucose and EOC cancer stage at diagnosis, while 
glycemia has been explored in relation to risk of EOC 
development in one single study with negative find-
ings [7]. The literature concerning the impact of the 
exposure of interest on treatment outcomes in EOC 
patients is somewhat less scant. Lamkin and col-
leagues tested the hypothesis of higher pre-surgical 
glucose levels associated with shorter time to recur-
rence and disease-specific survival in 74 patients with 
ovarian cancer and used an independent set of 125 
ovarian cancer cases for results validation. The au-
thors observed a relationship between higher 
pre-surgical glucose levels in ovarian cancer patients 
and decreased survival time and disease free interval. 
Confirmatory results came from the validation set. 
However, a not negligible limitation to the generali-
zability of this study results was introduced by glu-
cose assessment in plasma samples collected in non 
fasting conditions. As clearly stated by the authors 
themselves, the measurement of glucose levels with-
out standardizing for fasting duration introduced a 
considerable source of variability, particularly when 
working on a mixed set including both diabetic and 
non-diabetic patients. In addition, postload plasma 
glucose and fasting glucose were proven to differen-
tially impact cancer mortality [25-27].  
This invites further caution in comparing results 
from our study with the findings from the work of 
Lamkin and colleagues.  
Highly standardized operative conditions at 
blood collection and processing, along with the ex-
clusive use of the institutional certified laboratories of 
clinical pathology for fasting glucose measurement, 
represent the major strengths of this study. Similarly, 
standardized procedures were applied at the time of 
tissue handling and specimen preparation, which 
both occurred under the supervision of a pathologist 
with renown expertise in gynecological cancers. The 
relatively large historic cohort and the simplicity of 
the scientific hypothesis stated and methods applied 
might add some value to our work.  
Among the main limitations, it is noteworthy the 
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lack of BMI data for the entire cohort. Missing values 
for a given exposure are extremely common when 
relying on data primarily collected for clinical pur-
poses. In addition, among the indicators of the sys-
temic metabolic asset closely related to glucose me-
tabolism, we exclusively focused on fasting glucose 
while not including in our analysis potentially rele-
vant markers, such as baseline insulin, insulin-like 
growth factor-I (IGF-I) and insulin-like growth fac-
tors. Unfortunately, serum measurements of such 
determinants were not available for these patients 
since, differently from the assessment of glycemia, 
their assessment is not encompassed into clinical rou-
tine.  
Conclusions 
In summary, we provide novel evidence of the 
association between pre-treatment fasting glucose and 
FIGO stage at diagnosis in a historic cohort of 147 
women diagnosed with EOC at the Regina Elena 
Cancer Institute of Rome. Although such evidence is 
non univocally interpretable, it might be in key with 
the hypothesis of a role of metabolic influxes on re-
nown prognostic factors, such as FIGO stage, in EOC. 
This latter hypothesis fuels active research in a still 
largely unexplored and extremely promising area of 
investigation in ovarian and other cancers [28-34]. 
Within this pipeline, future work from our group will 
be bidirectionally oriented. We aim to confirm our 
results in larger and prospectively conducted studies 
with both a districtual and systemic focus, i.e., fo-
cused on the evaluation of the role of determinants of 
glucose metabolism not only at an ovarian tissue lev-
el, but also on blood samples collected for pre-defined 
study purposes. Our approach will be effectively en-
riched by the use of immunophenotipying and on-
cogenomic techniques which will be coupled to the 
classical morphologic characterization. This strategy 
will hopefully contribute mechanistic insights perti-
nent to the molecular players and related pathways 
underlying the potential role of metabolic determi-
nants on risk stratification and treatment outcomes in 
EOC patients.  
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